TAPS+ enables simultaneous detection of methylation and genetic variants, unlocking new insights for precision oncology and translational research. Preserves DNA integrity in challenging clinically ...
DNAe, the Next-Generation Sequencing (NGS) company developing a transformative fully automated, sample-to-report diagnostics platform, today announces that it will be presenting brand-new data on ...
According to Mordor Intelligence, the global companion diagnostics market is valued at USD 8.70 billion in 2025 and is projected to surpass USD 15.62 billion by 2030, growing at a CAGR of 12.42% ...
News-Medical.Net on MSN
Redefining control and consistency in anaerobic microbiome workflows
Explore how smart automation enables precise, reproducible workflows in anaerobic microbiome research, improving accuracy and ...
New solution transforms fragile AI toolchains into tested, production-ready integrations to power AI workflows Prismatic MCP flow server MCP flow server for production-ready AI integrations. SIOUX ...
The global anatomic pathology market is projected to grow at a CAGR of nearly 8% during the forecast period. Market expansion is primarily driven by the growing incidence of cancer and chronic ...
It said it would take up most of the review's recommendations, including scrapping the English Baccalaureate (EBacc), a ...
The reforms, unveiled by Education Secretary Bridget Phillipson, follow recommendations from Professor Becky Francis’s ...
The acquisition, which enables Qiagen to enter the single-cell sequencing market, is expected to close in December and contribute $40 million to 2026 revenues.
Germany, France, and the UK lead the IVD market due to robust healthcare systems and government support. Key trends include personalized medicine, digital health, and the adoption of rapid and ...
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that six abstracts have been accepted for presentation at the Society for ...
Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results